

18<sup>th</sup> February, 2025

**BSE Limited**

P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) –US FDA Inspection at Piramal Pharma’s facility located at Turbhe**

Dear Sir/Madam,

This is to inform you that the US FDA conducted General GMP inspection at Piramal Pharma Limited's Turbhe facility from 11<sup>th</sup> February, 2025 to 17<sup>th</sup> February, 2025.

On conclusion of the inspection, a Form-483 was issued with 6 observations. Observations are largely around improvement of procedures and practices and not related to data integrity. The Company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines.

The Company remains committed to maintain a highest standards of compliance and is confident of effective closure of observations.

This is for your information and records.

Thank you,

Yours truly,

**For Piramal Pharma Limited**

**Tanya Sanish**  
**Company Secretary**

**Piramal Pharma Limited**

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India  
T: +91 22 3802 3000 / 4000; Email: [shareholders.ppl@piramal.com](mailto:shareholders.ppl@piramal.com)

[piramalpharma.com](http://piramalpharma.com)